Targeting the IL-22–IL-22R1 system might benefit chronic inflammatory diseases concerning the skin, chronic infections, pancreatitis, and so forth, although therapeutic modulation should be individualized [31]. The gene discussed is IL22RA1; the disease is pancreatitis.